◆英語タイトル:Amryt Pharma plc (AMYT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9976
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Amryt Pharma plc (Amryt) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products include Lojuxta for the treatment of adult HoFH and Episalvan for the treatment of PTW. The company is also developing a portfolio of pipeline candidates, AP101 and AP102 targeting multiple orphan diseases such as epidermolysis bullosa, acromegaly and Cushing’s disease. The company offers its products in European Economic Area (EEA) and Middle East. Amryt is headquartered in London, the UK.
Amryt Pharma plc (AMYT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Amryt Pharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Amryt Pharma plc, Medical Devices Deals, 2012 to YTD 2018 9
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
SomPharma Raises Funds in Series A Financing 11
Partnerships 12
Amryt Pharma Enters into Distribution Agreement with RCC Pharma 12
Amryt Pharma Enters into Agreement with INC Research 13
Licensing Agreements 14
Amryt Pharma Enters into Licensing Agreement with University College Dublin (UCD) 14
Aegerion Pharma Expands Licensing Agreement with Amryt Pharma 15
SomPharma Enters into Licensing Agreement with University of California, San Diego 16
Equity Offering 17
Amryt Pharma to Raise USD18 Million in Private Placement of Shares 17
Amryt Pharma Raises USD14.4 Million in Public Offering of Shares 19
Acquisition 20
Amryt Pharma Acquires Birken 20
Fastnet Equity Acquires Amryt Pharmaceuticals in Reverse Takeover Transaction 21
Amryt Pharma Acquires Som for USD4.3 Million 22
Amryt Pharma plc – Key Competitors 23
Amryt Pharma plc – Key Employees 24
Amryt Pharma plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Sep 26, 2018: Amryt Pharma: Interim Results 26
Apr 17, 2018: Amryt Pharma: Final Results For the 12 months to 31 December 2017 30
Sep 04, 2017: Amryt Pharma: Interim results for the six months ended 30 June 2017 39
Mar 30, 2017: Amryt Pharma Announces Final Results for the year ended 31 December 2016 45
Corporate Communications 46
Jan 24, 2018: Amryt Pharma: Senior Management Team Appointment 46
Mar 27, 2017: Amryt Pharma Announces Senior Management Appointment 47
Feb 09, 2017: Amryt Pharma Announces Directorate Change 48
Other Significant Developments 49
Jul 06, 2018: Amryt Pharma Announces Change of Registered Address 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Amryt Pharma plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Amryt Pharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Amryt Pharma plc, Deals By Therapy Area, 2012 to YTD 2018 8
Amryt Pharma plc, Medical Devices Deals, 2012 to YTD 2018 9
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
SomPharma Raises Funds in Series A Financing 11
Amryt Pharma Enters into Distribution Agreement with RCC Pharma 12
Amryt Pharma Enters into Agreement with INC Research 13
Amryt Pharma Enters into Licensing Agreement with University College Dublin (UCD) 14
Aegerion Pharma Expands Licensing Agreement with Amryt Pharma 15
SomPharma Enters into Licensing Agreement with University of California, San Diego 16
Amryt Pharma to Raise USD18 Million in Private Placement of Shares 17
Amryt Pharma Raises USD14.4 Million in Public Offering of Shares 19
Amryt Pharma Acquires Birken 20
Fastnet Equity Acquires Amryt Pharmaceuticals in Reverse Takeover Transaction 21
Amryt Pharma Acquires Som for USD4.3 Million 22
Amryt Pharma plc, Key Competitors 23
Amryt Pharma plc, Key Employees 24
Amryt Pharma plc, Other Locations 25
Amryt Pharma plc, Subsidiaries 25
List of Figures
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Amryt Pharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Amryt Pharma plc, Medical Devices Deals, 2012 to YTD 2018 9